Armata Pharmaceuticals, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $23.7M | $34.4M | $33.8M | $35.0M | $20.0M |
| Operating expenses | $41.5M | $47.6M | $45.4M | $42.5M | $28.3M |
| Operating income | -$36.6M | -$42.4M | -$40.9M | -$36.9M | -$23.8M |
| Interest expense | — | — | — | $0 | $64,000 |
| Pretax income | -$173.8M | -$18.9M | -$69.0M | -$36,917 | -$23.2M |
| Income tax expense | — | — | — | $0 | $0 |
| Net income | -$173.8M | -$18.9M | -$69.0M | -$36.9M | -$23.2M |
| Balance Sheet | |||||
| Cash and equivalents | $8.7M | $9.3M | $13.5M | $14.9M | $10.3M |
| Current assets | $10.7M | $11.3M | $19.2M | $27.0M | $15.0M |
| Total assets | $76.9M | $86.4M | $98.4M | $95.8M | $69.8M |
| Current liabilities | $8.9M | $48.2M | $16.5M | $24.9M | $4.8M |
| Total liabilities | $295.5M | $134.5M | $130.4M | $59.8M | $44.4M |
| Stockholders' equity | -$218.6M | -$48.0M | -$32.1M | $36.1M | $25.4M |
| Cash Flow Statement | |||||
| Cash from operations | -$25.8M | -$37.6M | -$47.4M | -$32.5M | -$23.6M |
| Depreciation and amortization | $1.5M | $1.3M | $972,000 | $892,000 | $1.2M |
| Stock-based compensation | $2.6M | $2.9M | $938,000 | $3.1M | $2.9M |
| Capital expenditure | $542,000 | $1.9M | $8.1M | $2.2M | $1.3M |
| Free cash flow | -$26.3M | -$39.4M | -$55.6M | -$34.7M | -$24.9M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 36.7K · Free float 47.0%
Annual filing data through FY ended December 31, 2025; float as of July 11, 2026.